



ProteoTech Inc.
14718 NE 87th Street
Redmond, WA 98052 USA

ProteoTech receives funding for two NIH research grants to study the cause, prevention and treatment of brain amyloid deposits associated with Alzheimer's disease

Redmond, WA, April 16, 1999 –The National Institutes of Health (NIH) has funded two research programs that may lead to (1) a closer understanding of the mechanisms involved in "plaque" and "tangle" formation, the underlying neuropathology of Alzheimer's disease, and (2) a preventative and potential treatment for brain amyloid protein deposits present in all patients with Alzheimer's disease. ProteoTech, Inc., a biotechnology company, has been awarded a total of \$371,487.

From the National Institute of Health, ProteoTech has received a \$227,501 Small Business Innovative Research (SBIR) Phase I award to further isolate and identify the active amyloid inhibitory ingredients in its proprietary natural plant derivative, PTI-00703TM. The title of the research project is "PTI-00703: A Potent Amyloid Inhibiting Agent for the Treatment of Alzheimer's Disease and Other Amyloidoses". The principal investigator is Gerardo Castillo, Ph.D., Director of Biochemistry, at ProteoTech.

Additionally, ProteoTech has been awarded a \$143,986 SBIR Phase I award from the NIH to further investigate the discovery of a proteoglycan structural abnormality that may be critical for the formation of the major pathological lesions, i.e., amyloid plaques and neurofibrillary tangles of Alzheimer's disease. The study also reconfirms the importance and involvement of specific proteoglycans in this disease. Research findings are expected to lead to the identification of novel therapeutics and diagnostics for Alzheimer's disease and other amyloid disorders. The principal investigator is Jacques Garrigues, Ph.D., Senior Research Scientist of Molecular Biology, at ProteoTech.

Since its inception, ProteoTech has identified several lead compounds for the treatment of Alzheimer's disease and other amyloid disorders, including PTI-00703™, a natural plant derivative demonstrated to inhibit Alzheimer's amyloid fibril formation and growth. ProteoTech has recently licensed the dietary supplement use of PTI-00703™, while it retains rights to develop the active amyloid inhibitory ingredients within PTI-00703™ as prescription pharmaceuticals.

ProteoTech Inc is a drug discovery Company focused on therapeutics for human disease, which involve "proteoglycans" in the disease pathogenesis. Proteoglycans are a group of specific complex carbohydrate-containing macromolecules which are synthesized by virtually all cells of the body and which play significant roles in the pathogenesis of a number of human diseases including Alzheimer's, Down's syndrome, diabetes, cancer, arthritis, atherosclerosis, heart disease and AIDS. For more information, please check out the press kit at www.milestones.org/client_PressKitContent.htm.

Contact: Lorraine Ruff, APR, B.Sc., Partner
Milestones, the critical thinking company
206.214.0050 or 206.786.1355